🚀 VC Portfolio Analysis Calculator
Professional-grade venture capital portfolio modeling and education platform
📈 Portfolio Parameters
📊 Portfolio Performance
Expected Multiple
Portfolio IRR
Break-Even Hit Rate
Required Win Multiple
📋 Quick Interpretation
🎯 Understanding Venture Capital Returns
Venture capital is fundamentally different from traditional investing. Success depends on a few massive winners compensating for many failures - this is called the "Power Law" of VC returns.
💰 What is a "Win Multiple"?
A multiple shows how much money you get back compared to your investment:
- 2x: $100K → $200K (doubled)
- 10x: $100K → $1M (great return)
- 100x: $100K → $10M (home run)
Real Example: A $250K investment in Facebook's Series A (2005) would be worth ~$200M today - an 800x multiple!
📈 Key Metrics Explained
Expected Multiple: Average return per dollar invested
Portfolio IRR: Annualized return percentage (like compound interest)
Break-Even Hit Rate: Minimum success rate needed to not lose money
Required Win Multiple: How big winners need to be given your failure rate
🎲 Monte Carlo Simulation
This runs 1,000+ random scenarios of your portfolio to show the range of possible outcomes. VC returns are highly variable - you might get lucky or unlucky.
10th Percentile (Worst Case)
90% chance you'll do better than this
50th Percentile (Median)
Most likely outcome
90th Percentile (Best Case)
10% chance of doing this well
🏥 MedTech Investment Stages & Success Rates
Medical technology investments have unique risk profiles at different stages due to regulatory requirements, clinical trials, and FDA approval processes.
| Stage | Typical Failure Rate | Expected Multiple (Winners) | Key Risks | Time to Exit |
|---|---|---|---|---|
| Pre-Clinical | 85-95% | 20-100x | Technology validation, IP | 8-12 years |
| Clinical Stage (Phase I/II) | 75-85% | 10-50x | Clinical trials, FDA approval | 6-10 years |
| Late Clinical (Phase III) | 60-75% | 5-25x | Regulatory approval, market access | 4-8 years |
| Commercial Stage | 40-60% | 3-15x | Market adoption, competition | 3-6 years |
| Digital Health/SaaS | 65-80% | 5-30x | Regulatory (if applicable), adoption | 5-8 years |
⚠️ MedTech Reality Check
Medical technology investments often take 2-3x longer and require 2-3x more capital than initially projected. Factor in:
- FDA approval delays and requirement changes
- Clinical trial recruitment challenges
- Reimbursement and health system adoption hurdles
- Need for follow-on capital throughout development
⚡ The Power Law of VC Returns
In a typical VC portfolio, returns follow a highly skewed distribution where a small number of investments drive almost all returns.
📊 Typical VC Fund Breakdown
- 1 company: Returns 10-100x (fund maker)
- 2-3 companies: Return 3-10x (solid wins)
- 3-5 companies: Return 1-3x (modest success)
- 5-10 companies: Return 0.1-1x (disappointing)
- 10+ companies: Total loss (failures)
💡 What This Means for You
- You need access to potential "grand slams"
- Portfolio size matters for diversification
- Can't predict which deals will be winners
- Follow-on capital is crucial for winners
- Time horizon must be 7-10+ years
🎯 Key Insight
The goal isn't to minimize failures - it's to maximize your exposure to potential massive winners while maintaining enough diversification to capture them.
🚨 Common Mistakes & Reality Checks
❌ What Doesn't Work
- Trying to pick only "safe" deals
- Insufficient portfolio diversification
- No reserves for follow-on investments
- Unrealistic timeline expectations
- Ignoring the power law dynamics
✅ What Works
- Focus on market size and potential
- Bet on exceptional teams
- Maintain disciplined portfolio construction
- Reserve capital for follow-ons
- Take a long-term view (10+ years)
🏆 Top-Tier VC Performance Standards
Understanding what elite venture capital firms like Andreessen Horowitz, Sequoia, and Benchmark achieve helps set realistic expectations and goals.
📊 Fund-Level Performance
| Top Decile VC | 25-40% IRR |
| Upper Quartile | 15-25% IRR |
| Median VC | 10-15% IRR |
| Bottom Quartile | 0-10% IRR |
🎯 Deal-Level Expectations
- Minimum viable return: 10x in 7-10 years
- Market size threshold: $10B+ TAM
- Ownership target: 15-25% fully diluted
- Growth expectations: 100%+ YoY (early stage)
- Category creation: Preference for new markets
💼 Portfolio Construction Strategies
Andreessen Horowitz Approach
- 30-40 companies per fund
- Initial check: $1-10M
- Reserve 2-3x initial for follow-ons
- Concentrated bets on winners
- Sector-focused expertise
Sequoia Capital Approach
- 20-25 companies per fund
- Higher initial ownership targets
- Strong follow-on discipline
- Long-term partnership model
- Board-level involvement
📈 Stage-Specific Benchmarks
| Investment Stage | Typical Check Size | Expected Multiple | Target IRR | Time Horizon | Failure Rate |
|---|---|---|---|---|---|
| Pre-Seed | $100K - $500K | 25-100x | 40-60% | 8-12 years | 90-95% |
| Seed | $500K - $2M | 15-50x | 30-45% | 7-10 years | 85-90% |
| Series A | $3M - $15M | 10-30x | 25-35% | 6-9 years | 75-85% |
| Series B | $10M - $30M | 5-20x | 20-30% | 5-8 years | 65-75% |
| Growth/Late | $25M - $100M+ | 3-10x | 15-25% | 3-6 years | 50-65% |
🔥 Sector-Specific Performance
Different sectors have varying risk-return profiles and success rates based on market dynamics, regulatory requirements, and capital intensity.
🧬 Biotech/Pharma
- Success Rate: 5-15%
- Winner Multiples: 10-1000x
- Time to Exit: 10-15 years
- Capital Intensity: Very High
🏥 MedTech/Devices
- Success Rate: 15-30%
- Winner Multiples: 5-50x
- Time to Exit: 7-12 years
- Capital Intensity: High
💻 Software/SaaS
- Success Rate: 20-35%
- Winner Multiples: 5-100x
- Time to Exit: 5-8 years
- Capital Intensity: Medium
🔋 Cleantech/Energy
- Success Rate: 10-25%
- Winner Multiples: 3-30x
- Time to Exit: 8-12 years
- Capital Intensity: Very High
🚨 The Harsh Reality
Most individual investors and smaller funds cannot achieve top-tier VC returns because:
- Deal Access: Best opportunities go to established funds first
- Check Size: Can't write large enough checks for meaningful ownership
- Due Diligence: Lack resources for proper evaluation
- Follow-on Capital: Can't participate in subsequent rounds
- Portfolio Support: Limited ability to help companies succeed
Recommendation: Be conservative with assumptions and realistic about your competitive position in the market.